December 15, 2017 06:49 AM ESTUpdated 11:28 AM
People
Peer Review

No­var­tis on­col­o­gy CEO Bruno St­rig­i­ni is call­ing it quits

John Carroll

Editor & Founder

No­var­tis on­col­o­gy chief Bruno St­rig­i­ni is on the way out of the phar­ma gi­ant.

In a brief state­ment No­var­tis point­ed­ly said that St­rig­i­ni had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times